000863043 001__ 863043
000863043 005__ 20210130001800.0
000863043 0247_ $$2doi$$a10.1186/s13054-019-2493-7
000863043 0247_ $$2ISSN$$a1364-8535
000863043 0247_ $$2ISSN$$a1466-609X
000863043 0247_ $$2Handle$$a2128/22237
000863043 0247_ $$2altmetric$$aaltmetric:61492331
000863043 0247_ $$2pmid$$apmid:31159847
000863043 0247_ $$2WOS$$aWOS:000470127200001
000863043 037__ $$aFZJ-2019-03165
000863043 082__ $$a610
000863043 1001_ $$0P:(DE-HGF)0$$aLiu, Jingjin$$b0
000863043 245__ $$aPost-stroke treatment with argon attenuated brain injury, reduced brain inflammation and enhanced M2 microglia/macrophage polarization: a randomized controlled animal study
000863043 260__ $$aHeidelberg$$bSpringer$$c2019
000863043 3367_ $$2DRIVER$$aarticle
000863043 3367_ $$2DataCite$$aOutput Types/Journal article
000863043 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1559637029_28594
000863043 3367_ $$2BibTeX$$aARTICLE
000863043 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000863043 3367_ $$00$$2EndNote$$aJournal Article
000863043 520__ $$aBackgroundIn recent years, argon has been shown to exert neuroprotective effects in an array of models. However, the mechanisms by which argon exerts its neuroprotective characteristics remain unclear. Accumulating evidence imply that argon may exert neuroprotective effects via modulating the activation and polarization of microglia/macrophages after ischemic stroke. In the present study, we analyzed the underlying neuroprotective effects of delayed argon application until 7 days after reperfusion and explored the potential mechanisms.MethodsTwenty-one male Wistar rats underwent transient middle cerebral artery occlusion or sham surgery randomly for 2 h using the endoluminal thread model. Three hours after transient middle cerebral artery occlusion induction and 1 h after reperfusion, animals received either 50% vol Argon/50% vol O2 or 50% vol N2/50% vol O2 for 1 h. The primary outcome was the 6-point neuroscore from 24 h to d7 after reperfusion. Histological analyses including infarct volume, survival of neurons (NeuN) at the ischemic boundary zone, white matter integrity (Luxol Fast Blue), microglia/macrophage activation (Iba1), and polarization (Iba1/Arginase1 double staining) on d7 were conducted as well. Sample size calculation was performed using nQuery Advisor + nTerim 4.0. Independent t test, one-way ANOVA and repeated measures ANOVA were performed, respectively, for statistical analysis (SPSS 23.0).ResultsThe 6-point neuroscore from 24 h to d7 after reperfusion showed that tMCAO Ar group displayed significantly improved neurological performance compared to tMCAO N2 group (p = 0.026). The relative numbers of NeuN-positive cells in the ROIs of tMCAO Ar group significantly increased compared to tMCAO N2 group (p = 0.010 for cortex and p = 0.011 for subcortex). Argon significantly suppressed the microglia/macrophage activation as revealed by Iba1 staining (p = 0.0076) and promoted the M2 microglia/macrophage polarization as revealed by Iba1/Arginase 1 double staining (p = 0.000095).ConclusionsArgon administration with a 3 h delay after stroke onset and 1 h after reperfusion significantly alleviated neurological deficit within the first week and preserved the neurons at the ischemic boundary zone 7 days after stroke. Moreover, argon reduced the excessive microglia/macrophage activation and promoted the switch of microglia/macrophage polarization towards the anti-inflammatory M2 phenotype. Studies making efforts to further elucidate the protective mechanisms and to benefit the translational application are of great value.
000863043 536__ $$0G:(DE-HGF)POF3-573$$a573 - Neuroimaging (POF3-573)$$cPOF3-573$$fPOF III$$x0
000863043 588__ $$aDataset connected to CrossRef
000863043 7001_ $$0P:(DE-HGF)0$$aNolte, Kay$$b1
000863043 7001_ $$0P:(DE-HGF)0$$aBrook, Gary$$b2
000863043 7001_ $$0P:(DE-Juel1)171712$$aLiebenstund, Lisa$$b3$$ufzj
000863043 7001_ $$0P:(DE-HGF)0$$aWeinandy, Agnieszka$$b4
000863043 7001_ $$0P:(DE-HGF)0$$aHöllig, Anke$$b5
000863043 7001_ $$0P:(DE-HGF)0$$aVeldeman, Michael$$b6
000863043 7001_ $$0P:(DE-Juel1)144347$$aWilluweit, Antje$$b7
000863043 7001_ $$0P:(DE-Juel1)131777$$aLangen, Karl-Josef$$b8
000863043 7001_ $$0P:(DE-HGF)0$$aRossaint, Rolf$$b9
000863043 7001_ $$00000-0002-7930-0270$$aCoburn, Mark$$b10$$eCorresponding author
000863043 773__ $$0PERI:(DE-600)2051256-9$$a10.1186/s13054-019-2493-7$$gVol. 23, no. 1, p. 198$$n1$$p198$$tCritical care$$v23$$x1364-8535$$y2019
000863043 8564_ $$uhttps://juser.fz-juelich.de/record/863043/files/document.pdf$$yOpenAccess
000863043 8564_ $$uhttps://juser.fz-juelich.de/record/863043/files/document.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000863043 909CO $$ooai:juser.fz-juelich.de:863043$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000863043 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)171712$$aForschungszentrum Jülich$$b3$$kFZJ
000863043 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)144347$$aForschungszentrum Jülich$$b7$$kFZJ
000863043 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131777$$aForschungszentrum Jülich$$b8$$kFZJ
000863043 9131_ $$0G:(DE-HGF)POF3-573$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$vNeuroimaging$$x0
000863043 9141_ $$y2019
000863043 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000863043 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000863043 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCRIT CARE : 2017
000863043 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000863043 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000863043 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000863043 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000863043 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000863043 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000863043 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000863043 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review
000863043 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCRIT CARE : 2017
000863043 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000863043 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000863043 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000863043 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000863043 9201_ $$0I:(DE-Juel1)INM-4-20090406$$kINM-4$$lPhysik der Medizinischen Bildgebung$$x0
000863043 980__ $$ajournal
000863043 980__ $$aVDB
000863043 980__ $$aUNRESTRICTED
000863043 980__ $$aI:(DE-Juel1)INM-4-20090406
000863043 9801_ $$aFullTexts